ORIGINAL PAPER
A recent overview of non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: pathophysiology, recognition, and management
1
Department of Biochemistry, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
2
Department of Internal Medicine, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
3
Department of Paediatric Diabetes, Auxology and Obesity, Institute of Paediatrics, Poznan University of Medical Sciences, Poznan, Poland
Submission date: 2023-05-02
Final revision date: 2023-07-07
Acceptance date: 2023-07-08
Publication date: 2023-12-15
Corresponding author
Dominika Podgórska
Rafał Podgórski, PhD, Department of Biochemistry, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
Rafał Podgórski, PhD, Department of Biochemistry, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
Pediatr Pol 2023;98(4):307-319
KEYWORDS
TOPICS
ABSTRACT
Congenital adrenal hyperplasia (CAH) is defined as a group of congenital, autosomal, and recessive disorders associated with functional limitations or deficiency of one of the key enzymes in the biosynthesis of steroid hormones leading to hypocortisolaemia and most frequently excessive androgen production. The most common abnormality is associated with 21-hydroxylase deficiency. Activity at the level of 20–70% of normal enzyme function leads to the development of a non-classic form of congenital adrenal hyperplasia (NCAH). In contrast to classic CAH, patients with NCAH manifest normal or partially mild cortisol deficiency and moderate hyperandrogenism without a deficit of mineralocorticoids. Due to nonspecific symptoms, NCAH is often never recognized or is misdiagnosed with polycystic ovary syndrome (PCOS). Recognition can be based on the measurement of 17-hydroxyprogesterone (17OHP) for screening purposes, but the cosyntropin stimulation test with a measurement of 17OHP should be the gold standard. Pharmacological treatment is initiated only in those who manifest significant clinical symptoms.
REFERENCES (138)
1.
Kaur J, Casas L, Bose HS. Lipoid congenital adrenal hyperplasia due to STAR mutations in a Caucasian patient. Endocrinol Diabetes Metab Case Rep 2016; 2016: 150119.
2.
Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
3.
Bremer AA, Miller WL. Regulation of Steroidogenesis. In: Cellular Endocrinology in Health and Disease. Ulloa-Aguirre A, Conn PM (Eds.). Academic Press, Boston 2014: 207-227.
4.
Lee SR, Lee S, Kim S, et al. Hydroxylation and sulfation of sex steroid hormones in inflammatory liver. J Biomed Res 2017; 31: 437-444.
5.
Azziz R, Zacur HA. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis. J Clin Endocrinol Metab 1989; 69: 577-584.
6.
Pang S, Clark A, Neto EC, et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993; 2: 105-139.
7.
Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 4133-4160.
8.
Podgórski R, Aebisher D, Stompor M, et al. Congenital adrenal hyperplasia: clinical symptoms and diagnostic methods. Acta Biochim Pol 2018; 65: 25-33.
9.
Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 2017; 23: 580-599.
10.
Stoupa A, González-Briceño L, Pinto G, et al. Inadequate cortisol response to the tetracosactide (Synacthen®) test in non-classic congenital adrenal hyperplasia: an exception to the rule? Horm Res Pediatr 2015; 83: 262-267.
11.
Delle Piane L, Rinaudo PF, Miller WL. 150 years of congenital adrenal hyperplasia: translation and commentary of De Crecchio’s classic paper from 1865. Endocrinology 2015; 156: 1210-1217.
12.
Pang S, Murphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55: 413-420.
13.
Krone N, Dhir V, Ivison HE, et al. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf) 2007; 66: 162-172.
14.
Decourt J, Jayle MF, Baulieu E. [Clinically late virilism with excretion of pregnanetriol and insufficiency of cortisol production]. Ann Endocrinol (Paris) 1957; 18: 416-422.
15.
El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017; 390: 2194-210.
16.
Trapp CM, Oberfield SE. Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids 2012; 77: 342-346.
17.
Parsa AA, New MI. Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2017; 165: 2-11.
18.
van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol 2004; 151 Suppl 3: U71-U75.
19.
Ginalska-Malinowska M. Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency – the next disease included in the neonatal screening program in Poland. Dev Period Med 2018; 22: 197-200.
20.
Nordenström A, Falhammar H. Management of endocrine disease: Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency. Eur J Endocrinol 2019; 180: R127-R145.
21.
Hannah-Shmouni F, Morissette R, Sinaii N, et al. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med 2017; 19: 1276-1279.
22.
New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4205-4214.
23.
Nandagopal R, Sinaii N, Avila NA, et al. Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families. Eur J Endocrinol 2011; 164: 977-984.
24.
Sumińska M, Bogusz-Górna K, Wegner D, et al. Non-classic disorder of adrenal steroidogenesis and clinical dilemmas in 21-hydroxylase deficiency combined with backdoor androgen pathway. Mini-review and case report. Int J Mol Sci 2020; 21: 4622.
25.
Tusie-Luna MT, Traktman P, White PC. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 1990; 265: 20916-20922.
26.
Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord 2009; 10: 77-82.
27.
Reisch N, Högler W, Parajes S, et al. A diagnosis not to be missed: nonclassic steroid 11β-hydroxylase deficiency presenting with premature adrenarche and hirsutism. J Clin Endocrinol Metab 2013; 98: E1620-E1625.
28.
Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997; 6: 1829-1834.
29.
Parajes S, Loidi L, Reisch N, et al. Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95: 779-788.
30.
Azziz R, Hincapie LA, Knochenhauer ES, et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999; 72: 915-925.
31.
Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87: 2611-2622.
32.
Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788.
33.
Lin-Su K, Harbison MD, Lekarev O, et al. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J Clin Endocrinol Metab 2011; 96: 1710-1717.
34.
Quintos JB, Vogiatzi MG, Harbison MD, et al. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 1511-1517.
35.
Wedell A, Ritzén EM, Haglund-Stengler B, et al. Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc Natl Acad Sci USA 1992; 89: 7232-7236.
36.
Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 181-192.
37.
Wedell A, Wedell A. Molecular genetics of 21- hydroxylase deficiency. Endocr Dev 2011; 20: 80-87.
38.
Krone N, Rose IT, Willis DS, et al. Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) cohort. J Clin Endocrinol Metab 2013; 98: E346-E354.
39.
Jha S, Turcu AF. Nonclassic congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2021; 50: 151-165.
40.
New MI, Abraham M, Gonzalez B, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA 2013; 110: 2611-2616.
41.
Dracopoulou-Vabouli M, Maniati-Christidi M, Dacou-Voutetakis C. The spectrum of molecular defects of the CYP21 gene in the Hellenic population: variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 2845-2848.
42.
Wedell A, Thilén A, Ritzén EM, et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994; 78: 1145-1152.
43.
Jääskeläinen J, Levo A, Voutilainen R, et al. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997; 82: 3293-3297.
44.
Bachega TASS, Billerbeck AEC, Marcondes JAM, et al. Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 2000; 52: 601-607.
45.
Bidet M, Bellanné-Chantelot C, Galand-Portier M-B, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009; 94: 1570-1578.
46.
Deneux C, Tardy V, Dib A, et al. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2001; 86: 207-213.
47.
Falhammar H, Wedell A, Nordenström A. Biochemical and genetic diagnosis of 21-hydroxylase deficiency. Endocrine 2015; 50: 306-314.
48.
Tardy V, Menassa R, Sulmont V, et al. Phenotype-genotype correlations of 13 rare CYP21A2 mutations detected in 46 patients affected with 21-hydroxylase deficiency and in one carrier. J Clin Endocrinol Metab 2010; 95: 1288-1300.
49.
Finkielstain GP, Chen W, Mehta SP, et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2011; 96: E161-E172.
50.
Carmina E. Pathogenesis and treatment of hirsutism in late-onset congenital adrenal hyperplasia. Reprod Med Rev 1995; 4: 179-187.
51.
Nakamura Y, Hornsby PJ, Casson P, et al. Type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. J Clin Endocrinol Metab 2009; 94: 2192-2198.
52.
Prete A, Auchus RJ, Ross RJ. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol 2022; 186: R1-R14.
53.
Pignatelli D, Pereira SS, Pasquali R. Androgens in congenital adrenal hyperplasia. Front Horm Res 2019; 53: 65-76.
54.
Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004; 15: 432-438.
55.
Blank SK, McCartney CR, Helm KD, et al. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med 2007; 25: 352-359.
56.
Dhayat NA, Dick B, Frey BM, et al. Androgen biosynthesis during minipuberty favors the backdoor pathway over the classic pathway: insights into enzyme activities and steroid fluxes in healthy infants during the first year of life from the urinary steroid metabolome. J Steroid Biochem Mol Biol 2017; 165: 312-322.
57.
Witchel SF. Non-classic congenital adrenal hyperplasia. Steroids 2013; 78: 747-750.
58.
Kohn B, Levine LS, Pollack MS, et al. Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 1982; 55: 817-827.
59.
Moran C, Azziz R, Carmina E, Det al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol 2000; 183: 1468-1474.
60.
Dacou-Voutetakis C, Dracopoulou M. High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche. J Clin Endocrinol Metab 1999; 84: 1570-1574.
61.
Voutilainen R, Jääskeläinen J. Premature adrenarche: etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 2015; 145: 226-236.
62.
Kashimada K, Ono M, Onishi T, et al. Clinical course of patients with nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in infancy and childhood. Endocr J 2008; 55: 397-404.
63.
Ostlere LS, Rumsby G, Holownia P, et al. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne. Clin Endocrinol (Oxf) 1998; 48: 209-215.
64.
Knowles RL, Khalid JM, Oerton JM, et al. Late clinical presentation of congenital adrenal hyperplasia in older children: findings from national paediatric surveillance. Arch Dis Child 2014; 99: 30-34.
66.
Skordis N, Shammas C, Phedonos AAP, et al. Genetic defects of the CYP21A2 gene in girls with premature adrenarche. J Endocrinol Invest 2015; 38: 535-539.
67.
Armengaud J-B, Charkaluk M-L, Trivin C, et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009; 94: 2835-2840.
68.
Balducci R, Boscherini B, Mangiantini A, et al. Isolated precocious pubarche: an approach. J Clin Endocrinol Metab 1994; 79: 582-589.
69.
Weintrob N, Dickerman Z, Sprecher E, et al. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height. Eur J Endocrinol 1997; 136: 188-195.
70.
Eyal O, Tenenbaum‐Rakover Y, Shalitin S, et al. Adult height of subjects with nonclassical 21-hydroxylase deficiency. Acta Paediatr 2013; 102: 419-423.
71.
Brunelli VL, Russo G, Bertelloni S, et al. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. J Pediatr Endocrinol Metab 2003; 16 Suppl. 2: 277-283.
72.
Wasniewska MG, Morabito LA, Baronio F, et al. Growth trajectory and adult height in children with nonclassical congenital adrenal hyperplasia. Horm Res Paediatr 2020; 93: 173-181.
73.
New MI, Gertner JM, Speiser PW, et al. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J Endocrinol Invest 1989; 12: 91-95.
74.
Bello R, Lazar L, Phillip M, et al. Compromised adult height in females with non-classical congenital adrenal hyperplasia diagnosed in childhood. Horm Res Paediatr 2023; 96: 465-472.
75.
Bano G, Phillips C, Tang S, et al. Diagnostic imaging in congenital adrenal hyperplasia – how does it help? Ann Clin Endocrinol Metabol 2020; 4: 7-10.
76.
Martinez-Aguayo A, Rocha A, Rojas N, et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 4583-4589.
77.
Claahsen-van der Grinten HL, Sweep FCGJ, Blickman JG, et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007; 157: 339-344.
78.
Claahsen-van der Grinten HL, Hulsbergen-van de Kaa CA, Otten BJ. Ovarian adrenal rest tissue in congenital adrenal hyperplasia – a patient report. J Pediat Endocrinol Metab 2006; 19: 177-182.
79.
Pignatelli D. Non-classic adrenal hyperplasia due to the deficiency of 21-hydroxylase and its relation to polycystic ovarian syndrome. Front Horm Res 2013; 40: 158-170.
80.
Stikkelbroeck Nike MML, Hermus Ad RMM, Schouten D, et al. Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol 2004; 14: 1802-1806.
81.
Guarnotta V, Niceta M, Bono M, et al. Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2020; 198: 105554.
82.
Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 4043-4088.
83.
Pezzuti IL, Barra CB, Mantovani RM, et al. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J Pediatr (Rio J) 2014; 90: 300-307.
84.
Barnes ND, Atherden SM. Diagnosis of congenital adrenal hyperplasia by measurement of plasma 17-hydroxyprogesterone. Arch Dis Child 1972; 47: 62-65.
85.
White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009; 5: 490-498.
86.
Wong T, Shackleton CH, Covey TR, et al. Identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioimmunoassays. Clin Chem 1992; 38: 1830-1837.
87.
King JL, Naber JM, Hopkin RJ, et al. Antenatal corticosteroids and newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 2001; 155: 1038-1042.
88.
Chan CL, McFann K, Taylor L, et al. Congenital adrenal hyperplasia and the second newborn screen. J Pediatr 2013; 163: 109-113.e1.
89.
Gurian EA, Kinnamon DD, Henry JJ, et al. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006; 117: 1915-1921.
90.
Trapp CM, Speiser PW, Oberfield SE. Congenital adrenal hyperplasia: an update in children. Curr Opin Endocrinol Diabetes Obes 2011; 18: 166-170.
91.
Kao PC, Machacek DA, Magera MJ, et al. Diagnosis of adrenal cortical dysfunction by liquid chromatography-tandem mass spectrometry. Ann Clin Lab Sci 2001; 31: 199-204.
92.
Ambroziak U, Kępczyńska‐Nyk A, Kuryłowicz A, et al. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. Clin Endocrinol (Oxf) 2016; 84: 23-29.
93.
Demirci C, Witchel SF. Congenital adrenal hyperplasia. Dermatol Ther 2008; 21: 340-353.
94.
Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93: 527-533.
95.
Maffazioli GDN, Bachega TASS, Hayashida SAY, et al. Steroid screening tools differentiating nonclassical congenital adrenal hyperplasia and polycystic ovary syndrome. J Clin Endocrinol Metab 2020; 105: e2895-e2902.
96.
Papadakis G, Kandaraki EA, Tseniklidi E, et al. Polycystic ovary syndrome and NC-CAH: distinct characteristics and common findings. A systematic review. Front Endocrinol (Lausanne) 2019; 10: 388.
97.
Oriolo C, Fanelli F, Castelli S, et al. Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone. J Endocrinol Invest 2020; 43: 1499-1509.
98.
Choi J-H, Kim G-H, Yoo H-W. Recent advances in biochemical and molecular analysis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Pediatr Endocrinol Metab 2016; 21: 1-6.
99.
Brønstad I, Breivik L, Methlie P, et al. Functional studies of novel CYP21A2 mutations detected in Norwegian patients with congenital adrenal hyperplasia. Endocr Connect 2014; 3: 67-74.
100.
Moran C, Azziz R, Weintrob N, et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 3451-3456.
101.
Hicks RA, Yee JK, Mao CS, et al. Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia. Metabolomics 2014; 10: 123-131.
102.
Janzen N, Peter M, Sander S, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007; 92: 2581-2589.
103.
Livadas S, Bothou C. Management of the female with non-classical congenital adrenal hyperplasia (NCCAH): a patient-oriented approach. Front Endocrinol 2019; 10: 366.
104.
Nimkarn S, New MI. Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Mol Cell Endocrinol 2009; 300: 192-196.
105.
Simpson JL, Rechitsky S. Prenatal genetic testing and treatment for congenital adrenal hyperplasia. Fertil Steril 2019; 111: 21-23.
106.
New MI, Tong YK, Yuen T, et al. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J Clin Endocrinol Metab 2014; 99: E1022-E1030.
107.
Carlson AD, Obeid JS, Kanellopoulou N, et al. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol 1999; 69: 19-29.
108.
Thilén A, Woods KA, Perry LA, et al. Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency. Acta Paediatr 1995; 84: 894-898.
109.
Weintrob N, Israel S, Lazar L, et al. Decreased cortisol secretion in nonclassical 21-hydroxylase deficiency before and during glucocorticoid therapy. J Pediatr Endocrinol Metab 2002; 15: 985-991.
110.
Falhammar H, Filipsson Nyström H, Wedell A, et al. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Eur J Endocrinol 2013; 168: 331-341.
111.
Falhammar H, Filipsson H, Holmdahl G, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 110-116.
112.
Clayton PE, Miller WL, Oberfield SE, et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002; 58: 188-195.
113.
Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 193-208.
114.
Bachelot A, Golmard JL, Dulon J, et al. Determining clinical and biological indicators for health outcomes in adult patients with childhood onset of congenital adrenal hyperplasia. Eur J Endocrinol 2015; 173: 175-184.
115.
Arlt W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95: 5110-5121.
116.
Ogilvie CM, Crouch NS, Rumsby G, et al. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol 2006; 64: 2-11.
117.
Nermoen I, Husebye ES, Svartberg J, et al. Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. Eur J Endocrinol 2010; 163: 453-459.
118.
Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev 2022; 43: 91-159.
119.
Rushworth RL, Torpy DJ, Falhammar H. Adrenal crises: perspectives and research directions. Endocrine 2017; 55: 336-345.
120.
Falhammar H, Frisén L, Norrby C, et al. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99: E2715-E2721.
121.
Mallappa A, Sinaii N, Kumar P, et al. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2015; 100: 1137-1145.
122.
Quinkler M, Dahlqvist P, Husebye ES, et al. A European Emergency Card for adrenal insufficiency can save lives. Eur J Intern Med 2015; 26: 75-76.
123.
Oliveira JC, Sousa FC, Campos ST, et al. Congenital adrenal hyperplasia in adolescence – a gynecological perspective. Ginekol Pol 2023; 94: 170-176.
124.
Falhammar H, Nordenström A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine 2015; 50: 32-50.
125.
Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012; 18: 146-170.
126.
Merke DP, Poppas DP. Management of adolescents with congenital adrenal hyperplasia. Lancet Diabetes Endocrinol 2013; 1: 341-352.
127.
Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 1233-1257.
128.
Merke DP, Auchus RJ. Congenital Adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 2020; 383: 1248-1261.
130.
Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 89-94.
131.
Auchus RJ, Buschur EO, Chang AY, et al. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99: 2763-2770.
132.
Schröder MAM, Claahsen-van der Grinten HL. Novel treatments for congenital adrenal hyperplasia. Rev Endocr Metab Disord 2022; 23: 631-645.
133.
Dauber A, Kellogg M, Majzoub JA. Monitoring of therapy in congenital adrenal hyperplasia. Clin Chem 2010; 56: 1245-1251.
134.
Shibayama Y, Higashi T, Shimada K, et al. Liquid chromatography – tandem mass spectrometric method for determination of salivary 17α-hydroxyprogesterone: a noninvasive tool for evaluating efficacy of hormone replacement therapy in congenital adrenal hyperplasia. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 49-56.
135.
Turcu AF, Wannachalee T, Tsodikov A, et al. Comprehensive analysis of steroid biomarkers for guiding primary aldosteronism subtyping. Hypertension 2020; 75: 183-192.
136.
O’Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. J Clin Endocrinol Metab 2017; 102: 840-848.
137.
Engberg H, Butwicka A, Nordenström A, et al. Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: a total population study. Psychoneuroendocrinology 2015; 60: 195-205.
138.
Falhammar H, Torpy DJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as adrenal incidentaloma: a systematic review and meta-analysis. Endocr Pract 2016; 22: 736-752.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
